The first experience of using of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer

A. Doroshenko, V. Chernov, A. Medvedeva, R. Zeltchan, E. Slonimskaya, N. Varlamova, V. Skuridin, A. Dergilev, I. Sinilkin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. Materials and methods. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n=34) were injected with radioactive 99mTc-Al203, and Group II patients (n=30) received 99mTc-labeled phytate colloid. Results. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. At 18 hours after 99mTc-Al203 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II patients, SLNs were detected in 27 patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. Conclusion. The new radiopharmaceutical based on the 99mTc - Al203 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. Sensitivity and specificity of 99mTc - Al203 were 100% for both SPECT and intraoperative gamma probe identification.

Original languageEnglish
Article number012011
JournalIOP Conference Series: Materials Science and Engineering
Volume135
Issue number1
DOIs
Publication statusPublished - 2 Aug 2016

Fingerprint

Single photon emission computed tomography
Colloids
Technetium
Surgery
Phytic Acid
Radiopharmaceuticals
Alumina
cyhalothrin
Aluminum Oxide

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)

Cite this

The first experience of using of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. / Doroshenko, A.; Chernov, V.; Medvedeva, A.; Zeltchan, R.; Slonimskaya, E.; Varlamova, N.; Skuridin, V.; Dergilev, A.; Sinilkin, I.

In: IOP Conference Series: Materials Science and Engineering, Vol. 135, No. 1, 012011, 02.08.2016.

Research output: Contribution to journalArticle

@article{810c3d1ab07f47049d25a579ef6c68bd,
title = "The first experience of using of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer",
abstract = "Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. Materials and methods. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n=34) were injected with radioactive 99mTc-Al203, and Group II patients (n=30) received 99mTc-labeled phytate colloid. Results. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. At 18 hours after 99mTc-Al203 injection, the percentage of its accumulation in the SLN was 7-11{\%} (of the counts in the injection site) by SPECT and 17-31{\%} by gamma probe detection. In Group II patients, SLNs were detected in 27 patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in the SLN was 1.5-2{\%} out of the counts in the injection site by SPECT and 4-7{\%} by gamma probe. Conclusion. The new radiopharmaceutical based on the 99mTc - Al203 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. Sensitivity and specificity of 99mTc - Al203 were 100{\%} for both SPECT and intraoperative gamma probe identification.",
author = "A. Doroshenko and V. Chernov and A. Medvedeva and R. Zeltchan and E. Slonimskaya and N. Varlamova and V. Skuridin and A. Dergilev and I. Sinilkin",
year = "2016",
month = "8",
day = "2",
doi = "10.1088/1757-899X/135/1/012011",
language = "English",
volume = "135",
journal = "IOP Conference Series: Materials Science and Engineering",
issn = "1757-8981",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - The first experience of using of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer

AU - Doroshenko, A.

AU - Chernov, V.

AU - Medvedeva, A.

AU - Zeltchan, R.

AU - Slonimskaya, E.

AU - Varlamova, N.

AU - Skuridin, V.

AU - Dergilev, A.

AU - Sinilkin, I.

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. Materials and methods. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n=34) were injected with radioactive 99mTc-Al203, and Group II patients (n=30) received 99mTc-labeled phytate colloid. Results. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. At 18 hours after 99mTc-Al203 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II patients, SLNs were detected in 27 patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. Conclusion. The new radiopharmaceutical based on the 99mTc - Al203 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. Sensitivity and specificity of 99mTc - Al203 were 100% for both SPECT and intraoperative gamma probe identification.

AB - Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. Materials and methods. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n=34) were injected with radioactive 99mTc-Al203, and Group II patients (n=30) received 99mTc-labeled phytate colloid. Results. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. At 18 hours after 99mTc-Al203 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II patients, SLNs were detected in 27 patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. Conclusion. The new radiopharmaceutical based on the 99mTc - Al203 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. Sensitivity and specificity of 99mTc - Al203 were 100% for both SPECT and intraoperative gamma probe identification.

UR - http://www.scopus.com/inward/record.url?scp=84995550782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995550782&partnerID=8YFLogxK

U2 - 10.1088/1757-899X/135/1/012011

DO - 10.1088/1757-899X/135/1/012011

M3 - Article

VL - 135

JO - IOP Conference Series: Materials Science and Engineering

JF - IOP Conference Series: Materials Science and Engineering

SN - 1757-8981

IS - 1

M1 - 012011

ER -